Patient Rating:

No Rating Available?

Xinjian Chen, M.D.

Patient Rating:

No Rating Available?

Specialties

  • Pathology

Languages

  • Chinese
  • English

Clinical Details

Schedule An Appointment Clinical Office Address

Specialties

  • Pathology

Bio

Dr. Chen's scholarly emphasis is on mechanisms regulating immunity and immunological tolerance as well as mechanisms for immunodeficiency and autoimmune diseases.

Board Certification and Academic Information

Academic Departments Pathology - Associate Professor
Academic Divisions Anatomic Pathology
Board Certification American Board of Pathology (Anatomic)

Academic Profile

Research Interests

  • Allergy and Immunology

Board Certification and Academic Information

Academic Departments Pathology - Associate Professor
Academic Divisions Anatomic Pathology
Board Certification American Board of Pathology (Anatomic)

Academic Office Locations

Academic Office Phone Number Academic Office Address
Huntsman Cancer Hospital
Surgical Pathology
1950 Circle of Hope
Salt Lake City, UT 84112

Academic Bio

Dr. Chen is an assistant professor of pathology at the University of Utah School of Medicine. He received his MD from Hunan Medical College in Changsha, China and completed residency training in pathology at Emory University School of Medicine. Dr. Chen also completed a fellowship in dermatology at Stanford University Medical Center as well as a fellowship in pathology at Emory University School of Medicine.

Education

Education History

Type School Degree
Fellowship Emory University School of Medicine
Immunology
Fellow
Residency Emory University School of Medicine
Anatomical Pathology
Resident
Fellowship Stanford University Medical Center
Dermatology Research
Fellow
Internship/Residency University of Alabama at Birmingham
Internal Medicine
Intern/Resident
Doctoral Training University of Alabama at Birmingham
Immunology
Ph.D.
Residency Hunan Medical College
Pathology
Resident
Professional Medical Hunan Medical College
Medicine
M.D.

Publications

Selected Provider Publications

Journal Article

  1. Bramwell K, Ma Y, Chen X, Weiss J, Zachary J, Teuscher C, Weiss J (2014). Lysosomal beta-Glucuronidase Regulates Lyme and Rhuematoid Arthritis Severity. J Clin Invest, 124, 311-320.
  2. Chen X corresponding author, Jensen P (2014). The Biological Function of HLA-DO (H2-O). Crit Rev Immunol, 34, 215-25.
  3. Wang Y, Chen X, Tsai S, Thomas A, Shizuru JA, Cao TM (2013). Fine mapping of the Bmgr5 quantitative trait locus for allogeneic bone marrow engraftment in non-myeloablated mice. Immunogenetics, 65, 585-96.
  4. Gu Y, Jensen P, Chen X (2013). Immunodeficiency and autoimmunity in H2-O deficient mice. J Immunol, 1(190), 126-37.
  5. Chen X, Wang Y, Tsai S, Thomas A, Shizurur JA, Cao TM (2013). Pathways analysis of differential gene expression induced by engrafting doses of total body irradiation for allogeneic bone marrow transplantation in mice. Immunogenetics, 65, 597-607.
  6. Anker CJ, Ribas A, Grossmann AH, Chen X, Grossmann KF (2013). Severe liver and skin toxicity following radiation and vemurafenib in metastatic melanoma. J Clin Oncol, 31, e283-7.
  7. Li Q, Shakya A, Guo X, Zhang H, Tantin D, Jensen PE, Chen X (2012). Constitutive nuclear localization of NFAT in Foxp3+ regulatory T cells independent of calcineurin activity. J Immunol, 188, 4268-77.
  8. Huffaker TB, Hu R, Runtsch MC, Bake E, Chen X, Zhao J, Round JL, Baltimore D, OConnell RM (2012). Epistasis between microRNAs 155 and 146a during T cell-mediated antitumor immunity. Cell Rep, 2, 1697-709.
  9. Chen LL, Chen X, Choi Haesun, Sang Hongxun, et al (2011). Exploiting antitumor immunity to overcome relapse and improve remission duration. Cancer Immunol Immunother, 61, 1113-1124.
  10. Chen X (2010). B Lymphocytes, potent Antigen presenting cells for preferential expansion of allo-reactive FoxP3+ CD4 Regulatory T Cells. Recent Patents on. Recent Pat Endocr Metab Immune Drug Discov, 4, 100-110.
  11. Chen LC, Deldado J, Jensen PE, Chen X (2009). Direct expansion of human allospecific FoxP3+CD4+ regulatory T cells with allogeneic B cells for therapeutic application. J Immunol, 183, 4094-4102.
  12. Chen X correspondence author, Jensen, PE (2008). MHC class II antigen presentation and immunological abnormalities due to deficiency of MHC class II and its associated genes. Exp Mol Pathol, 85, 40-4.
  13. Chen X, Jensen PE (2008). The role of B lymphocytes as antigen-presenting cells. Arch Immunol Ther Exp (Warsz), 56, 77-83.
  14. Chen X correspondence author and Jensen PE (2007). Cutting Edge: Primary B-lymphocytes preferentially expand allogeneic FoxP3+ CD4 T cells. J Immunol, 179, 2046-50.
  15. Chen X correspondence author Reed-Loisel LM, Karlsson L, Jensen PE (2006). H2-O expression in primary dendritic cells. J Immunol, 176, 3548-56.
  16. Chen X correspondence author, Jensen PE (2004). The Expression of HLA-DO (H2-O) in B Lymphocytes. Immunol Res, 29, 19-28.
  17. Chen X, Jensen PE, Li S (2003). A useful marker to distinguish florid follicular hyperplasia from follicular lymphoma by flow cytometry. Am J Clin Pathol, 119, 842-51.
  18. Nagarajan UM, Chen X, Beresford GW, Nilsen R, Jensen PE, Boss JM (2002). Class II transactivator is required for maximal expression of HLA-DOB in B cells. J Immunol, 168, 1780-6.
  19. Chen X, Laur O, Kambayashi T, Li S, Bray RA, Weber DA, Karlsson L, Jensen PE (2002). Regulated expression of human histocompatibility leukocyte antigen (HLA)-DO during antigen-dependent and antigen-independent phases of B cell development. Journal of Experimental Medical Sciences, 195, 1053.
  20. Robbins PB, Lin Q, Goodnough JB, Tian H, Chen, X and Khavari PA (2001). In vivo restoration of laminin 5 b3 expression and function in junctional epidermolysis bullosa. Proc Natl Acad Sci U S A, 24(98), 5193-8.
  21. Jensen, PE, Weber DA, Thayer WP, Chen X, Dao CT (1999). HLA-DM and the MHC class II antigen presentation pathway. Immunol Res, 20, 195-205.
  22. Martin F, Chen X, Kearney JF (1998). Development of VH81X transgene bearing B cells in fetus and adult: sites for expansion and deletion in conventional and CD5/B1 lineage cells. International Immunology, 9, 493-505.
  23. Chen X, Martin F, Forbush KA, Perlmutter RM, Kearney JF (1997). Evidence for selection of a population of self-reactive B cells into the splenic marginal zone. International Immunology, 9, 27-41.
  24. Chen X, Kearney JF (1996). Generation and function of natural self-reactive B lymphocytes. Semin Immunol, 8, 19-27.
  25. Chen X, Matsura Y, Kearney JF (1994). CD5 Transgenic mice. Current Topics in Microbiology and Immunology, 194, 209-217.
  26. Solvason N, Chen S, Shu F, Kearney JF (1992). The fetal momentum in mice and humans: A site enriched for precursors of CD5 B cells early in development. Ann N Y Acad Sci, 651, 10-20.
  27. Chen X, Lin C (1985). Lack of estrogen receptor on breast lymphoma. Human Pathology, 18, 84-86.

Clinical Trials

Video & News